Edwards Lifesciences (EW) Gross Profit (2009 - 2026)

Edwards Lifesciences' Gross Profit history runs 18 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• In Q1 2026, Gross Profit rose 15.74% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $4.9 billion (up 11.8% YoY), while the FY2025 annual figure was $4.7 billion, up 9.52% from the prior year.
• Gross Profit was $1.3 billion for Q1 2026 at Edwards Lifesciences, up from $1.2 billion in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $1.3 billion in Q1 2026 to a low of $528.7 million in Q4 2022.
• Historically, Gross Profit has averaged $1.1 billion across 5 years, with a median of $1.1 billion in 2024.
• The sharpest annual moves came in 2022 and 2023: Gross Profit slumped 48.18% in 2022, then soared 92.06% in 2023.
• A 5-year view of Gross Profit shows it stood at $528.7 million in 2022, then surged by 92.06% to $1.0 billion in 2023, then increased by 7.7% to $1.1 billion in 2024, then climbed by 12.16% to $1.2 billion in 2025, then grew by 4.84% to $1.3 billion in 2026.
• The last three Gross Profit figures came in at $1.3 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.